Halozyme Therapeutics (NASDAQ:HALO) Given New $149.00 Price Target at Citizens Jmp

Halozyme Therapeutics (NASDAQ:HALO) had its price target hoisted by analysts at Citizens Jmp from $93.00 to $149.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp‘s target price points to a potential upside of 41.61% from the company’s current price.

HALO has been the subject of a number of other research reports. HC Wainwright increased their target price on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. Stifel Nicolaus set a $130.00 price objective on Halozyme Therapeutics in a report on Friday, October 16th. Finally, Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $106.09.

Halozyme Therapeutics Stock Down 14.4%

Shares of NASDAQ HALO traded down $17.74 during mid-day trading on Friday, reaching $105.22. 1,273,209 shares of the company’s stock were exchanged, compared to its average volume of 1,949,201. The firm has a market capitalization of $11.94 billion, a price-to-earnings ratio of 31.89, a PEG ratio of 0.49 and a beta of 0.92. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The business has a fifty day simple moving average of $115.26 and a 200 day simple moving average of $84.57. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.09. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The business had revenue of $492.97 million for the quarter, compared to analysts’ expectations of $491.63 million. During the same quarter in the previous year, the business posted $1.72 EPS. Halozyme Therapeutics’s revenue for the quarter was up 39.1% on a year-over-year basis. As a group, equities analysts expect that Halozyme Therapeutics will post 8.32 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock worth $13,538,046 in the last three months. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Mather Group LLC. raised its stake in shares of Halozyme Therapeutics by 48.9% during the 3rd quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 136 shares in the last quarter. North Dakota State Investment Board grew its stake in shares of Halozyme Therapeutics by 4.3% in the third quarter. North Dakota State Investment Board now owns 3,598 shares of the biopharmaceutical company’s stock valued at $397,000 after buying an additional 147 shares in the last quarter. CoreCap Advisors LLC grew its stake in shares of Halozyme Therapeutics by 98.0% in the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 150 shares in the last quarter. Fifth Third Wealth Advisors LLC grew its stake in shares of Halozyme Therapeutics by 3.5% in the third quarter. Fifth Third Wealth Advisors LLC now owns 4,515 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 151 shares in the last quarter. Finally, Twin Capital Management Inc. increased its holdings in Halozyme Therapeutics by 1.4% during the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 161 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Revenue rose 39% year over year to a record $493 million, while royalty revenue grew 44% to $341 million. Adjusted earnings of $2.39 per share also topped the roughly $2.30 consensus estimate. Halozyme Q3 results and guidance
• Positive Sentiment: Halozyme raised its 2026 guidance, forecasting $1.86 billion–$1.925 billion in revenue and non-GAAP EPS of $8.75–$9.05. It also expanded ENHANZE collaboration agreements with three existing partners, with three programs advancing into Phase 1 development. Halozyme Q3 earnings and guidance
• Negative Sentiment: HALO fell after the earnings release even though results exceeded estimates and guidance increased. The available reports flag the share-price decline but do not identify a specific reason for the negative market reaction. Halozyme sales surprise, but stock drops

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.